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ABSTRACT
Background: People have used Annona muricata (A. muricata) leaves traditionally as tea drinks. Traditional 
use of A. muricata leaves is as an infusion which is closed to water extract. The potential health benefit of A. 
muricata tea leaves that is traditionally used for maintaining health which lately is being used by cancer patients. 
Therefore it is urgent to verify the safety of A. muricata leaves extract. 
Method: A randomized double blind placebo controlled trial was conducted on 30 colorectal cancer out 
patients who had undergone primary tumor resection. Twenty eight subjects completed the study, divided into 
two groups, namely ethanol-soluble fraction of A. muricata leaves water extract (ESFAM) (n = 14), and placebo 
(n = 14) for 8 weeks. Peripheral blood samples were withdrawn from subjects by venipuncture at baseline and 
at the end of the study period. 
Results: The effect on bone marrow can be considered to be safe. The measure in indices of organs function, 
i.e liver and kidney also showed similar results and within normal range after supplementation. The dose given 
to the subjects is safe and highly tolerable, as shown by very few (6.7%) of patients complained intolerable 
adverse effects. 
Conclusion: This study indicates the safety of ESFAM supplementation. 
Keywords: colorectal cancer, Annona muricata leaves, adverse effect, vital organs
ABSTRAK
Latar Belakang: Daun Annona muricata (A. muricata/sirsak) telah digunakan secara tradisional sebagai 
minuman teh. Penggunaan rebusan daun A. muricata merupakan sediaan yang mirip dengan ekstrak air. 
Potensi manfaat kesehatan teh daun A. muricata yang secara tradisional digunakan untuk menjaga kesehatan 
akhir-akhir ini juga dimanfaatkan oleh pasien kanker. Oleh karena itu sangat mendesak untuk memverifikasi 
keamanan ekstrak daun A. muricata.
Metode: Uji klinik acak terkontrol (doble blind RCT) dilakukan pada 30 pasien kanker kolorektal yang telah 
menjalani reseksi tumor primer. Dua puluh delapan subjek menyelesaikan penelitian selama 8 minggu, dibagi 
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menjadi dua kelompok, yaitu kelompok ethanol-soluble fraction of A. muricata leaves water extract (ESFAM) 
(n = 14), dan plasebo (n = 14). Sampel darah perifer diperiksa pada awal dan pada akhir masa studi.
Hasil: Efek pada sumsum tulang dapat dianggap aman. Fungsi hati dan ginjal juga menunjukkan hasil yang 
sama dan dalam rentang normal setelah suplementasi. Dosis yang diberikan kepada subjek aman dan sangat 
ditoleransi, hanya sedikit (6,7%) dari pasien mengeluh efek samping.
Simpulan: Penelitian ini menunjukkan keamanan suplementasi ESFAM.
Kata kunci: kanker kolorektal, daun Annona muricata, efek samping, organ vital
INTRODUCTION
Some of Annonaceous acetogenins, biologically 
active compounds found in members of family 
Annonaceae, showed a powerful anti-tumor activities.1 
Nowadays, 34 acetogenins have been recognized in 
the leaves of Annona muricata (A. muricata).2 The 
primary site of action of the acetogenins is complex I 
of the electron transport chain in mitochondria which 
is more selective against tumorous than normal cells.3, 4 
In several areas in the world, tea leaves or decoction 
of A. muricata Linn helps cure several diseases.5-7 
People have used A. muricata leaves traditionally as tea 
drinks.8 Traditional use of A. muricata leaves is as an 
infusion which is closed to water extract. The potential 
health benefit of A. muricata tea leaves is traditionally 
used for maintaining health and lately is being used 
by cancer patients. Therefore it is urgent to verify the 
safety of A. muricata leaves extract. 
This study is part of clinical study on A. muricata 
leaves extract for colorectal cancer. The findings are 
not only of academic interest but also to provide public 
with evident-based-research information on the safety 
of this traditional medicine that sometimes constitutes 
the only affordable source of health care. This study is 
the first study supplementing colorectal cancer patients 
with ethanol-soluble fraction of A. muricata leaves water 
extract (ESFAM) and monitoring its safety.
METHOD
The subjects were colorectal cancer (CRC) 
patients at Cipto Mangunkusumo Hospital, Faculty of 
Medicine, Universitas Indonesia, Jakarta, Indonesia, 
after having experienced surgery for complete 
primary tumor resection. The protocol of this study 
was accepted by Medical Ethics Committee, Faculty 
of Medicine, Universitas Indonesia (No. 406/H2.F1/
ETIK/2013). Participation in the study was voluntary, 
and written informed consent was asked prior to the 
study. The clinical trial was cataloged on ClinicalTrials.
gov under the identifier NCT02439580.
Male and female CRC patients older than 30 years 
who were willing to consume one capsule per day 
of A. muricata extract or a placebo as an additional 
treatment throughout the study period were recruited 
to the study. The patients should also have satisfactory 
hematological and biochemical function and a 
Karnofsky performance status of ≥ 60%. 
The exclusion criterias were as follow: uncontrolled 
hypertension (untreated systolic blood pressure 
>160 mm Hg, or diastolic blood pressure > 95 mm 
Hg); serious heart problems; upper limit of alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), and creatinine are 111 U/L, 123 U/L, 3.6 mg/
dL respectively; a disability rendering them unable to 
communicate verbally; or a history of cancers other 
than colorectal (such as non-melanoma skin cancer, 
basal cell carcinoma, and squamous cell carcinoma) 
in the past five years. Pregnant or lactating women, 
and those using inadequate contraception, were 
also excluded. In addition, patients taking other 
investigational drugs, patients with hereditary non-
polyposis colorectal cancer (HNPCC), and patients 
consuming probiotic supplementation during the 
study period were also excluded to avoid potentially 
conflicting conditions and treatments.
The A. muricata extract investigated in this study 
was a standardized vacuum dried extract (Zirzak 
Orac) made by Javaplant, Central Java, Indonesia, 
containing 0.018% acetogenin (w/w). Zirzak further 
fractionated using ethanol to produce ethanol-soluble 
fraction of water extract (ESFAM). ESFAM contains 
0.36% acetogenin (w/w) or 3.6 mg/g, and a 10 g water 
extract is equivalent to a 2 g ethanolic fraction. In this 
study, the CRC patients took either 300 mg of ESFAM 
or maltose as a placebo in the form of a capsule after 
breakfast. 
The patients were randomly assigned into either 
ESFAM or placebo in a randomized double-blind 
placebo-controlled trial (RCT). Block randomization 
(four patients per block) was performed. Supplementation 
was given for eight weeks. Peripheral blood samples 
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were taken from subjects by venipuncture at baseline 
and at the end of the study period.
The results were analysed using SPSS for windows 
software version 22 (SPSS Inc., USA). Descriptive 
statistical analyses were conducted to present patients’ 
characteristics. Differences in means for normally 
distributed continuous variables were examined using 
independent t-tests. Differences in means within group 
for normally distributed continuous variables were 
examined paired sample t-test. Non-normally distributed 
data was examined by non-parametric tests. The Saphiro 
Wilk test was used to test the normality of the data.
RESULTS
Of 253 subjects on the list from the two centers, 
30 subjects met the inclusion and exclusion criterias 
and consented to take part in the trial and were 
allocated randomly into two groups (n = 15), namely 
supplementation and control group. A total of 30 
subjects participated in this study, and 28 subjects aged 
30-80 years (x = 50.2 years) completed the study in 
placebo (n = 14) and A. muricata leaves extracts (n = 
14). The baseline characteristics of subjects are shown 
in Table 1. which were comparable between the groups.
The evaluation of the organ function was determined 
using metabolic profile and blood count test. Tests 
performed as part of the blood count panel include the 
following: hemoglobin (Hb), hematocrite, red blood 
cell, platelet, leukocytes count. Tests performed as part 
of the metabolic profile panel included the following: 
albumin, AST, ALT, creatinine, blood urea nitrogen 
(BUN). 
The outcome variables, i.e. blood count, metabolic 
profile, and albumin were comparable in the two groups 
at baseline, and all those variables were normally 
distributed (p > 0.05; Shapiro Wilk test). The between-
group comparability analysis found that randomization 
ensured equal distribution of all variables (Table 2).
The mean number of days of taking the supplements 
was 56 days, and the percentage of subjects completing 
the trial (meet the compliance criteria of more than 
85% supplement tablet taken) was 93.33%, in each 
group of both study groups. The results of the present 
study showed a high adherence rate, 93.33% of the 
subjects were reported taking at least 85% of tablets, 
and categorized as complete participation. 
Two subjects were withdrawn and discontinued 
intervention for the following reasons: suffered from 
anal pain (n = 1) and the condition was getting worse 
(n = 1) caused by the chemotherapy and radiotherapy, 
also her housing area was flooded. Hence only few 
subjects (6.7%) in each group experienced probable 
intolerant side effects, thus the intervention was found 
to be highly acceptable to the subjects.
In general, the overall biochemical parameters 
(Table 3) before and after supplementation were 
considered within the normal range of the values, 
means that ESFAM did not decrease erythrocyte, 
platelet, and leucocyte count. The effect on bone 
marrow can be considered to be safe. 
The measure in indices of organs function, i.e liver 
and kidney also showed similar results. The change of 
ALT and AST were not significantly different between 
groups, and within normal range after supplementation 
(Figure 1 and 2). 
Table 2. Biochemical parameters of the subjects at baseline
ESFAM (n = 15)
mean ± SD
Placebo (n = 15)
mean ± SD Normal range p value**
Eritrosit 4.71 ± 0.27 4.49 ± 0.8 3.8-4.8.106/μL 0.319
Hemoglobin 12.67 ± 1.63 12.58 ± 1.51 13.0-17.0 g/dL 0.881
Hematokrit 37.89 ± 3.89 38.06 ± 4.01 40.0-50.0 % 0.909
Trombosit 243.27 ± 51.27 296.27 ± 121.5 150-400. 103/μL 0.136
Leukosit 6.75 ± 1.61 7.47 ± 2.96 5.00-10.00. 103/μL 0.415
ALT 21.21 ± 11.38 16.79 ± 9.19 < 37 U/L 0.103
AST 29.29 ± 15.86 22.71 ± 9.29 < 41 U/L 0.208
Kreatinin 1 (0.88-1.23)* 0.85 (0.7-1.03)* 0.6-1.2 mg/dL 0.186
Ureum 26.93 ± 16.80 23.25 ± 6.90 < 50 mg/dL 0.629
*median (25th, 75th percentiles) for non-normally distributed data; ** Independent sample t-test was performed for normally distributed data, 
Mann-Whitney U test for non-normally distributed data; ESFAM: ethanol-soluble fraction of A. Muricata; ALT: alanine aminotransferase; 
AST: aspartate aminotransferase
Table 1. Medical history of the subjects in each group
Groups Between 
group 
difference 
p value *
ESFAM
n = 15
Placebo
n = 15
Gender (%)
Male
Female
66.7
33.3
66.7
33.3
1.000
Age (year) 50.97 ± 14.8 52.21 ± 10.2 0.792
Chemotherapy (%)
Received
Not received
80.0
20.0
73.3
26.7
1.000
Tumor Stage (%)
I-II
III-IV
26,7
73.3
33,3
66.7
1.000
*) chi-square test was performed; ESFAM: ethanol-soluble fraction of A. 
muricata
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phytochemicals is one of the purposes of this study. 
This study might be catagorized as a proof-of-concept 
(PoC) study, defined as a clinical trial to determine if 
a treatment (drug) is biologically active or inactive. In 
general, they are phase I/II studies - which, investigate 
the safety profile, dose level and response to new 
drugs. PoC studies usually use surrogate markers as 
endpoints.9
This study was motivated by empirically usage of A. 
muricata leaves as traditional tea drink that is currently 
being studied on the developing effort of treating some 
types of cancers. In vitro and animal studies have been 
conducted using the extract of these leaves.10,11 One 
of cancers that are becoming a serious public health 
problem in Asia especially Indonesia is CRC 12-14
From the beginning of the supplementation phase, 
there were no appreciable differences between the 
study groups on socio-economic status, medical 
history, biochemical parameters, and nutritional status. 
The biochemical parameters were in the normal range. 
The patients recruited were in the range from capable in 
caring for most of their need to normal, no complaints, 
no evidence of disease. This condition is probably the 
most important factor to allow subjects in completing 
the eight weeks supplementation. Hence, only 6.7% 
patients were withdrawn, but their characteristics did 
not differ from the subjects who completed the trial. 
Study in Scotland on 55–64 year old CRC patients, 
reported that the screening of subjects showed 
socioeconomic deprivation as a strong predictor of 
participation.15 
In this study, most subjects (70%) have advanced 
tumor staging (stage III-IV) but it is comparable between 
the two groups. Likewise, the socioeconomic status and 
race/ethnicity category are also comparable. Hence these 
factors did not influence the study outcome. 
Subjects participate in this study are mainly male 
(66.7%), only 33.3% are female. The avarages of age 
are 50.9 and 52.2 years in ethanol-soluble fraction 
Figure 1.    Changes of SGPT in each group of CRC patients 
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Table 3. Laboratory analysis between groups 
ESFAM (n = 15)
mean ± SD
Within-
group 
difference 
p-value
Control (n = 15)
mean ± SD Within-group difference 
p-value
Between-
group 
difference 
p-value**Baseline Endline baseline endline
Erythrocyte counts 4.71 ± 0.28 4.72 ± 0.392 0.944 4.45 ± 0.82 4.44 ± 0.86 0.964 0.941
Haemoglobin 
concentration
12.69 ±1.69 12.79 ± 2.07 0.582 12.42 ± 1.43 12.57 ± 1.69 0.539 0.867
Hematocrite 38.01 ± 4.01 38.42 ± 4.86 0.475 37.74 ± 3.96 38.24±4.67 0.487 0.912
Platelet count 244.93 ± 52.79 240.57 ± 76.93 0.735 308 ± 116.93 267.07 ± 124.83 0.226 0.613
Leucocyte count 6.725 ± 1.67 7.20 ± 2.18 0.416 7.63 ± 3 8.15 ± 5.81 0.604 0.679
ALT 21,21 ± 11,38 17,5 ± 5,06 0.340 16.79 ± 9.19 17.14 ± 10.87 0.769 0.645
AST 29.29 ± 15.86 26.93 ± 12.97 0.168 22.71 ± 9.29 26.21 ± 14.13 0.583 0.175
Creatinin 1.0 (0.88-1.23)* 1.0 (0.70-1.03)* 0.088 0.85 (0.7-1.03) 0.9 (0.68-1.03) 0.432 0.755
Ureum 26.93 ± 16,80 27.07 ± 19,01 0 .371 23,25 ± 6,90 22,74 ± 5,87 0.929 0.370
*Median (25th, 75th percentiles) for non- normally distributed data; **Independent sample t-test was performed for normally distributed data, Mann-Whitney U 
test for non-normally distributed data; ALT: alanine aminotransferase; AST: aspartate aminotransferase
DISCUSSION
This study is part of study that identified the effect 
of A. muricata leaves extract in CRC patients, designed 
to correlate between in vivo human study and in vitro 
experiment. The correlation is aimed to overcome 
the limitation in understanding the bioavailability of 
phytochemical by which the health benefits depend 
on. To know the safety doses of biologically active 
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of water extract (ESFAM) and placebo group, 
respectively. This is in line with epidemiological 
studies in Asia that CRC patients are predominated 
by male and the risk are increased with age.16 Another 
study reported that a more than fivefold increase of 
CRC incidence between ages 55–59 and 80+ years 
was observed for women. While in men, a more than 
fourfold increase from the youngest to the oldest (55-
80) age group was observed.17
The majority of the subjects received chemotherapy 
because chemotherapy is one of currently main options 
for cancer treatment. The number of subjects received 
chemotherapy is comparable between the two groups. 
There are six and five subjects in ESFAM and placebo 
group, respectively receiving chemotherapy as well 
as blood withdrawn at the same time points. Hence 
chemotherapy has no influence on study outcome. 
The dosage of 300 mg of ESFAM in this study was 
based on safety data, efficacy and feasibility. Safety 
consideration is based on acute toxicity experiment in 
animal as part of this study and history of traditional 
use, whilst the efficacy is based on antitumor activity in 
mouse and in vitro test as part of this study. The defined 
dose was also based on the highest concentration of 
actogenin at affordable cost.5,8
The eight week supplementation study are based 
on several studies especially on the effect of vitamins 
or fruits on inflammatory markers. Duration of the 
studies vary between one month to three years. Study 
on the influence of antioxidant supplementation on 
plasma C-reactive protein (CRP) concentrations 
among active and passive smokers was conducted for 
an average of 58 days. Result of that study showed a 
significant change on CRP level with 24% reduction 
after supplementation. Other study among Type II 
diabetic patients also showed significant reduction of 
48% after tocopherol supplementation for one month.18 
Orange and blackcurrent juice supplementation among 
patients with perpheral arterial diseases for four weeks 
also significantly decreased CRP level.19
The organ function, liver as well as kidney, are 
not affected during supplementation in the present 
study. Hematological parameter measured in this 
study consist of platelet, erythrocyte, leukocytes 
count, and hemoglobin. Supplementation did not 
give any significant adverse effects on all parameters 
of hematology, the mean of all parameters relatively 
remain in a normal range, means that supplementation 
did not reduce the bone marrow function, unlike 
conventional chemotherapy. The dose given to the 
subjects is safe and highly tolerable, as shown by very 
few (6.7%) of patients complained intolerable adverse 
effects. This fact indicates the feasibility of adding 
ESFAM as adjuvant therapy. 
Since these dietary compounds are not classified 
as drugs, A. muricata extracts do not require official 
approval to be available for consumption. Therefore, 
a thorough evaluation on their toxicity and drug 
interactions are necessary to ensure the safety.
CONCLUSION
This study indicates the safety of ESFAM 
supplementation.
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